Global Infectious Disease Diagnostics Market Assessment, By Product [Reagents, Kits, and Consumables, Instruments, Software], By Sample Type [Blood and Components, Urine, Other], By Setting [Laboratory Testing, Point-of-Care Testing], By Type of Testing [Molecular Tests, Serological Tests, Antigen Tests, Culture Tests, Blood Tests, Imaging Tests], By Indication [Bacterial Infections, Viral Infections, CNS Infections, Cardiovascular Infections, Fungal Infections, GI Infections, Sexually Transmitted Diseases, Other], By End-user [Diagnostic Laboratories, Academic And Medical Institutes, Hospitals, Ambulatory Clinics, Home Healthcare, Other], By Region, Opportunities and Forecast, 2017-2031F

Global infectious disease diagnostics market is expected to experience rapid growth due to the growing prevalence of infectious diseases, availability of a diverse range of diagnostic tests, and increasing preference for point-of-care diagnostic testing techniques.

Home>Industry Reports>Global Infectious Disease Diagnostics Market Assessment, Opportunities and Forecast, 2017-2031F

Global infectious disease diagnostics market is projected to witness a CAGR of 6.17% during the forecast period 2024-2031, growing from USD 27.78 billion in 2023 to USD 44.85 billion in 2031F. Infectious disease diagnostics involve the identification of the causative agent of an infectious disease, such as bacteria, viruses, fungi, or parasites, in a patient with a compatible clinical illness. The process is essential for determining the most effective treatment. Diagnostic methods include laboratory tests, such as blood, urine, and tissue samples, as well as imaging scans to reveal evidence of the microbe causing the disease. The detection of the pathogen can be done through cultivation, isolation in cell culture, and identification biochemically, antigenically, or genetically. Additionally, specific immune responses and molecular technologies are used for accurate diagnosis, especially in low-resource settings.

The infectious disease diagnostics market is expected to thrive under the influence of factors like growing prevalence of infectious diseases, availability of a diverse range of diagnostic tests, and the increasing preference for point-of-care diagnostic testing techniques. The development of innovative disease diagnosis and monitoring technologies by key players in the industry is greatly contributing to the expansion of the market. Increasing investments for improving disease model analysis, and the strategic activities of key players is also contributing to the market growth.

However, the growth of infectious disease diagnostics market may be hindered by a lack of awareness of novel diagnostic solutions, absence of compiled regulatory guidelines, and lower positivity rates due to inferior laboratory conditions. Market players are actively involved in strategic product launches and business tactics to expand the market.

In February 2023, Thermo Fisher Scientific recently announced the release of Applied Biosystems TaqPath PCR kits designed specifically for diagnosing infectious diseases. These kits are effective in detecting diseases such as Multi-Drug Resistant Tuberculosis (MDR-TB), M. Tuberculosis complex (MTB), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV). Moreover, they can be used for genetic analysis (HLA B27). The Central Drugs Standard Control Organization (CDSCO) has approved these kits, and they will be produced in India in partnership with Mylab Discovery Solutions, a leading healthcare company.

Growing Prevalence of Infectious Diseases

Infectious diseases have been on the rise in the 21st century, with outbreaks such as COVID-19, SARS, and swine flu with a devastating impact on lives and livelihoods globally. Factors contributing to the emergence and spread of infectious diseases include ecological, environmental, or demographic factors that place people in increased contact with a previously unfamiliar microbe, as well as increasing prevalence of these factors. The growing prevalence of infectious diseases is directly proportional to the demand for infectious disease diagnostic solutions, further expanding the market. Infectious diseases are one of the leading causes of death globally and a suitable treatment plan be effectively utilized through efficient diagnostics.

According to the World Economic Forum, annually, infectious diseases, such as malaria, HIV, and tuberculosis, are the cause of death for over 2.8 million people, and more than 1.7 billion people require treatment for at least one neglected tropical disease, globally. In addition, epidemic-prone infectious diseases such as COVID-19 and Ebola are anticipated to claim thousands to millions of lives before control and preventive measures can be effective.

Availability of a Diverse Range of Diagnostic Tests

A diverse range of diagnostic tests is available for infectious diseases, including laboratory tests, rapid diagnostic tests, serological testing, and polymerase chain reaction (PCR) testing. These tests can detect antibodies, antigens, and specific microorganisms to aid in the diagnosis of infectious diseases. Laboratory tests use samples of blood, urine, sputum, or other fluids to identify microorganisms through staining, culturing, or molecular methods. Rapid diagnostic tests, which are available in various formats and platforms, provide rapid results to inform clinical decision-making and enable point-of-care management. Serological testing looks for antibodies to verify previous exposure, while PCR testing detects the genetic material of microorganisms. These diverse testing methods play a crucial role in accurate and timely diagnosis of infectious diseases. The diverse range is anticipated to contribute to the expansion of the market. Market players offer a variety of rapid diagnostic kits for different diseases.

In July 2023, EMPE Diagnostics launched mfloDx MDR-TB test kit for rapid diagnosis of tuberculosis and antibiotic resistance. The mfloDx MDR-TB test kit, developed in Genome Valley, provides clear yes/no results in a fraction of the time compared to traditional methods. It's recognized by the World Health Organization and approved by the Central Drugs Standard Control Organization, poised to change tuberculosis diagnostics globally.

Dominance of Laboratory Testing Segment While Fast Growth for PoC Testing

The laboratory testing segment is expected to lead the market with a larger value share throughout the assessment period due to its widespread application areas and efficacy percentage. Clinical laboratory tests encompass a wide range of services, such as complete blood count, basic metabolic panel, genetic testing, and clinical chemistry. While point-of-care testing is anticipated to grow at a higher CAGR owing to the rising rate of adoption of such technologies in diagnostics and the increasing availability of rapid diagnostics test kits. The growth in point-of-care testing is driven by factors like the increased demand for at-home testing and the development of innovative services, including personalized medication selection and dosing based on genetic testing. Market participants are dedicated to expanding their point-of-care portfolio through the launch of new rapid test kits.

For instance, in June 2023, Agdia, Inc. launched a new rapid and field-deployable RNA-based assay to detect Blueberry scorch virus (BlScV). The test has outperformed all commercially available serological (ELISA) tests and matches the performance of the most well-established PCR methods presently in use. The rapid diagnostic kit is called AmplifyRP XRT for BlScV.

Molecular Tests to Dominate the Market

The molecular tests segment is anticipated to dominate the infectious disease diagnostics market. Molecular diagnostics, including techniques such as DNA microarray analysis, is one of the fastest-growing areas in infectious disease identification. Molecular diagnostics is a modern solution for detecting parasitic, bacterial, and viral infections. Unlike traditional testing methods, these tests are more advanced and overcome the drawbacks of manually prepared media, longer turnaround duration, and poor sensitivity. They are highly accurate and reliable, making them an essential tool in the field of medical diagnosis.

For instance, in November 2023, Roche launched the LightCycler PRO System which uses the reliable technology of the LightCycler Systems that preceded it. The new system offers better performance and is more user-friendly, while bridging the gap between translational research and in-vitro diagnostics. The LightCycler PRO System is a great addition to Roche's molecular PCR testing portfolio, which includes solutions for various healthcare professionals. These solutions cater to those performing research as well as those testing patients for cancer, infectious diseases, and other public health challenges.

Asia-Pacific to be the Fastest Growing Region

Asia-Pacific is experiencing a growing incidence of infectious diseases. It is due to factors such as poverty, overpopulation, inadequate preventive health systems, and increasing population. The region is a hotspot for emerging infectious diseases, with new variants of cholera and dengue being reported. Despite impressive improvements in health and healthcare infrastructure, infectious diseases remain the major cause of death in the region. The share of deaths due to infectious diseases is increasing in the Asia-Pacific. In the region, Southeast Asia has a higher growth rate due to climatic and economic reasons for the widespread of infectious diseases.

According to the 'Health at a Glance: Asia-Pacific 2022' report published by WHO in 2023, Southeast Asia accounted for the largest number of tuberculosis cases globally in 2020, about 43% of the total cases. Among the countries and territories most affected by tuberculosis in 2020 were India (26.0% of tuberculosis cases globally), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), and Bangladesh (3.6%).

Future Market Scenario (2024 – 2031F)

The diagnostic industry is witnessing growing regulatory approvals for infectious disease diagnostic solutions, which are expected to be marketed in near future, further boosting the market. For instance, the Biomedical Advanced Research and Development Authority (BARDA) has supported a diverse portfolio of medical solutions and these products have received a total of 86 FDA approvals, licensures, or clearances. Similarly, the Infectious Diseases Society of America (IDSA) has highlighted the need for new incentives and regulatory changes to spur R&D for new antibiotics and flexible regulations to allow innovative test development to keep pace with emerging infectious diseases. The increasing regulatory approved products for infectious disease diagnosis are anticipated to land the market in future and bring a healthy competition among key players. The FDA has approved a number of diagnostic devices and authorized the emergency use of uncleared devices for infectious diseases, including influenza and respiratory syncytial virus.

In February 2023, The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test. This test is capable of detecting and differentiating influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19. The Lucira COVID-19 & Flu Home Test is a single-use kit that can be used at home. The test provides results from self-collected nasal swab samples in around 30 minutes.

Report Scope

“Infectious Disease Diagnostics Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global infectious disease diagnostics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute

Details

Base Year of the Analysis

2023

Historical Period

2017-2022

Forecast Period

2024-2031F

Projected Growth Rate

CAGR of 6.17% between 2024 and 2031F

Revenue Forecast in 2031

USD 44.85 billion

Units

Revenue in USD billion

Segments Covered

Product, Sample Type, Setting, Type of Testing, Indication, End-user

Regions Covered

North America, Europe, South America, Asia-Pacific, Middle East and Africa

Key Companies Profile

Becton Dickinson & Company, Cepheid Inc., Abbott Laboratories, BioMerieux SA, Hologic Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Thermo Fisher Scientific Inc., DiaSorin SpA, F. Hoffmann-La Roche AG

Customization Scope

15% free report customization with purchase

Pricing and Purchase Options

Avail the customized purchase options to fulfill your precise research needs

Delivery Format

PDF and Excel through email (subject to the license purchased)

In this report, global infectious disease diagnostics market has been segmented into the following categories: 

·         By Product

o   Reagents, Kits, and Consumables

o   Instruments

o   Software

·         By Sample Type

o   Blood and Components

o   Urine

o   Other

·         By Setting

o   Laboratory Testing

o   Point-of-Care Testing

·         By Type of Testing

o   Molecular Tests

o   Serological Tests

o   Antigen Tests

o   Culture Tests

o   Blood Tests

o   Imaging Tests

·         By Indication

o   Bacterial Infections

o   Viral Infections

o   CNS Infections

o   Cardiovascular Infections

o   Fungal Infections

o   GI Infections

o   Sexually Transmitted Diseases

o   Other

·         By End-user

o   Diagnostic Laboratories

o   Academic And Medical Institutes

o   Hospitals

o   Ambulatory Clinics

o   Home Healthcare

o   Other

·         By Region

o   North America

o   Europe

o   Asia-Pacific

o   South America

o   Middle East and Africa

Key Players Landscape and Outlook

These companies have a strong market presence with a vast product portfolio to offer in the field of diagnostics and research. With the growing infectious disease scenario, these players have strengthened their offerings through collaborations, mergers and acquisitions, and other market tactics.

In April 2023, Biosynex SA announced that it had completed its acquisition of Chembio Diagnostics, Inc. The combination of the two companies' technologies and product portfolios, and the combination of market opportunities, will be important growth drivers for the combined entity. Additionally, significant operational synergies are expected in procurement, research and diagnostics logistics, and production.

In July 2023, Novacyt announced its acquisition of Yourgene Health for approximately EUR 16.7 million (USD 21.2 million) in cash. Yourgene Health, located in Manchester, the United Kingdom, offers a range of molecular diagnostic tests for prenatal screening, male infertility, thrombosis risk, and cystic fibrosis. In addition, the company provides genomic medicine services to healthcare, research, and biopharmaceutical clients.

Key Players Operating in the Global Infectious Disease Diagnostics Market are:

·         Becton Dickinson & Company

·         Cepheid Inc.

·         Abbott Laboratories

·         BioMerieux SA

·         Hologic Inc.

·         Bio-Rad Laboratories Inc.

·         Danaher Corporation

·         Thermo Fisher Scientific Inc.

·         DiaSorin SpA

·         F. Hoffmann-La Roche AG

Markets and Data report answers the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments and the market size and growth of each segment?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global infectious disease diagnostics market, you may approach our team at info@marketsandata.com

Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Executive Summary

4.       Global Infectious Disease Diagnostics Market Outlook, 2017-2031F

4.1.    Market Size & Forecast

4.1.1. By Value

4.1.2. By Volume

4.2.    By Product

4.2.1.Reagents, Kits, and Consumables

4.2.2.Instruments

4.2.3.Software

4.3.    By Sample Type

4.3.1.Blood and Components

4.3.2.Urine

4.3.3.Other

4.4.    By Setting

4.4.1.Laboratory Testing

4.4.2.Point-of-Care Testing

4.5.    By Type of Testing

4.5.1.Molecular Tests

4.5.2.Serological Tests

4.5.3.Antigen Tests

4.5.4.Culture Tests

4.5.5.Blood Tests

4.5.6.Imaging Tests

4.6.    By Indication

4.6.1.Bacterial Infections

4.6.2.Viral Infections

4.6.3.CNS Infections

4.6.4.Cardiovascular Infections

4.6.5.Fungal Infections

4.6.6.GI Infections

4.6.7.Sexually Transmitted Diseases

4.6.8.Other

4.7.    By End-user

4.7.1.Diagnostic Laboratories

4.7.2.Academic And Medical Institutes

4.7.3.Hospitals

4.7.4.Ambulatory Clinics

4.7.5.Home Healthcare

4.7.6.Other

4.8.    By Region

4.8.1.  North America

4.8.2.  Europe

4.8.3.  Asia-Pacific

4.8.4.  South America

4.8.5.  Middle East and Africa

4.9.    By Company Market Share (%), 2023

5.       Global Infectious Disease Diagnostics Market Outlook, By Region, 2017-2031F

5.1.    North America*

5.1.1.Market Size & Forecast

5.1.1.1.   By Value

5.1.1.2.   By Volume

5.1.2.By Product

5.1.2.1.   Reagents, Kits, and Consumables

5.1.2.2.   Instruments

5.1.2.3.   Software

5.1.3.By Sample Type

5.1.3.1.   Blood and Components

5.1.3.2.   Urine

5.1.3.3.   Other

5.1.4.By Setting

5.1.4.1.   Laboratory Testing

5.1.4.2.   Point-of-Care Testing

5.1.5.By Type of Testing

5.1.5.1.   Molecular Tests

5.1.5.2.   Serological Tests

5.1.5.3.   Antigen Tests

5.1.5.4.   Culture Tests

5.1.5.5.   Blood Tests

5.1.5.6.   Imaging Tests

5.1.6.By Indication

5.1.6.1.   Bacterial Infections

5.1.6.2.   Viral Infections

5.1.6.3.   CNS Infections

5.1.6.4.   Cardiovascular Infections

5.1.6.5.   Fungal Infections

5.1.6.6.   GI Infections

5.1.6.7.   Sexually Transmitted Diseases

5.1.6.8.   Other

5.1.7.By End-user

5.1.7.1.   Diagnostic Laboratories

5.1.7.2.   Academic And Medical Institutes

5.1.7.3.   Hospitals

5.1.7.4.   Ambulatory Clinics

5.1.7.5.   Home Healthcare

5.1.7.6.   Other

5.1.8.United States*

5.1.8.1.   Market Size & Forecast

5.1.8.1.1.     By Value

5.1.8.1.2.     By Volume

5.1.8.2.   By Product

5.1.8.2.1.     Reagents, Kits, and Consumables

5.1.8.2.2.     Instruments

5.1.8.2.3.     Software

5.1.8.3.   By Sample Type

5.1.8.3.1.     Blood and Components

5.1.8.3.2.     Urine

5.1.8.3.3.     Other

5.1.8.4.   By Setting

5.1.8.4.1.     Laboratory Testing

5.1.8.4.2.     Point-of-Care Testing

5.1.8.5.   By Type of Testing

5.1.8.5.1.     Molecular Tests

5.1.8.5.2.     Serological Tests

5.1.8.5.3.     Antigen Tests

5.1.8.5.4.     Culture Tests

5.1.8.5.5.     Blood Tests

5.1.8.5.6.     Imaging Tests

5.1.8.6.   By Indication

5.1.8.6.1.     Bacterial Infections

5.1.8.6.2.     Viral Infections

5.1.8.6.3.     CNS Infections

5.1.8.6.4.     Cardiovascular Infections

5.1.8.6.5.     Fungal Infections

5.1.8.6.6.     GI Infections

5.1.8.6.7.     Sexually Transmitted Diseases

5.1.8.6.8.     Other

5.1.8.7.   By End-user

5.1.8.7.1.     Diagnostic laboratories

5.1.8.7.2.     Academic and medical institutes

5.1.8.7.3.     Hospitals

5.1.8.7.4.     Ambulatory clinics

5.1.8.7.5.     Home healthcare

5.1.8.7.6.     Other

5.1.9.Canada

5.1.10.    Mexico

*All segments will be provided for all regions and countries covered

5.2. Europe

5.2.1.Germany

5.2.2.France

5.2.3.Italy

5.2.4.United Kingdom

5.2.5.Russia

5.2.6.Netherlands

5.2.7.Spain

5.2.8.Turkey

5.2.9.Poland

5.3. Asia-Pacific

5.3.1.India

5.3.2.China

5.3.3.Japan

5.3.4.Australia

5.3.5.Vietnam

5.3.6.South Korea

5.3.7.Indonesia

5.3.8.Philippines

5.4. South America

5.4.1.Brazil

5.4.2.Argentina

5.5. Middle East & Africa

5.5.1.Saudi Arabia

5.5.2.UAE

5.5.3.South Africa

6.       Market Mapping, 2023

6.1. By Product

6.2. By Sample Type

6.3. By Setting

6.4. By Type of Testing

6.5. By Indication

6.6. By End-user

6.7. By Region

7.       Macro Environment and Industry Structure

7.1. Demand Supply Analysis

7.2. Import Export Analysis

7.3. Value Chain Analysis

7.4. PESTEL Analysis

7.4.1.       Political Factors

7.4.2.       Economic System

7.4.3.       Social Implications

7.4.4.       Technological Advancements

7.4.5.       Environmental Impacts

7.4.6.       Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5. Porter’s Five Forces Analysis

7.4.7.       Supplier Power

7.4.8.       Buyer Power

7.4.9.       Substitution Threat

7.4.10.    Threat from New Entrant

7.4.11.    Competitive Rivalry

8.       Market Dynamics

8.1. Growth Drivers

8.2. Growth Inhibitors (Challenges and Restraints)

9.       Regulatory Framework and Innovation

9.1. Clinical Trials

9.2. Patent Landscape

9.3. Regulatory Approvals

9.4. Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.                     Competition Matrix of Top Five Market Leaders

10.2.                     Market Revenue Analysis of Top Five Market Leaders (in %, 2023)

10.3.                     Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.                     SWOT Analysis (For Five Market Players)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.                   Becton Dickinson & Company

13.1.1.    Company Details

13.1.2.    Key Management Personnel

13.1.3.    Products & Services

13.1.4.    Financials (As reported)

13.1.5.    Key Market Focus & Geographical Presence

13.1.6.    Recent Developments

13.2.                   Cepheid Inc.

13.3.                   Abbott Laboratories

13.4.                   BioMerieux SA

13.5.                   Hologic Inc.

13.6.                   Bio-Rad Laboratories Inc.

13.7.                   Danaher Corporation

13.8.                   Thermo Fisher Scientific Inc.

13.9.                   DiaSorin SpA

13.10.                F. Hoffmann-La Roche AG

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.   Strategic Recommendations

15.   About Us & Disclaimer

List of Figures

Figure 1. Global Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 2. Global Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 3. Global Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 4. Global Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 5. Global Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 6. Global Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 7. Global Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 8. Global Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 9. Global Infectious Disease Diagnostics Market Share (%), By Region, 2017-2031F

Figure 10. North America Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 11. North America Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 12. North America Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 13. North America Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 14. North America Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 15. North America Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 16. North America Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 17. North America Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 18. North America Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F

Figure 19. United States Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 20. United States Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 21. United States Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 22. United States Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 23. United States Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 24. United States Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 25. United States Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 26. United States Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 27. Canada Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 28. Canada Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 29. Canada Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 30. Canada Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 31. Canada Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 32. Canada Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 33. Canada Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 34. Canada Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 35. Mexico Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 36. Mexico Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 37. Mexico Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 38. Mexico Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 39. Mexico Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 40. Mexico Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 41. Mexico Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 42. Mexico Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 43. Europe Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 44. Europe Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 45. Europe Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 46. Europe Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 47. Europe Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 48. Europe Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 49. Europe Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 50. Europe Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 51. Europe Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F

Figure 52. Germany Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 53. Germany Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 54. Germany Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 55. Germany Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 56. Germany Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 57. Germany Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 58. Germany Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 59. Germany Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 60. France Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 61. France Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 62. France Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 63. France Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 64. France Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 65. France Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 66. France Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 67. France Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 68. Italy Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 69. Italy Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 70. Italy Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 71. Italy Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 72. Italy Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 73. Italy Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 74. Italy Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 75. Italy Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 76. United Kingdom Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 77. United Kingdom Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 78. United Kingdom Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 79. United Kingdom Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 80. United Kingdom Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 81. United Kingdom Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 82. United Kingdom Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 83. United Kingdom Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 84. Russia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 85. Russia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 86. Russia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 87. Russia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 88. Russia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 89. Russia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 90. Russia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 91.

Figure 92. Russia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 93. Netherlands Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 94. Netherlands Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 95. Netherlands Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 96. Netherlands Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 97. Netherlands Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 98. Netherlands Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 99. Netherlands Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 100. Netherlands Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 101. Spain Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 102. Spain Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 103. Spain Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 104. Spain Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 105. Spain Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 106. Spain Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 107. Spain Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 108. Spain Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 109. Turkey Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 110. Turkey Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 111. Turkey Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 112. Turkey Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 113. Turkey Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 114. Turkey Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 115. Turkey Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 116. Turkey Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 117. Poland Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 118. Poland Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 119. Poland Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 120. Poland Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 121. Poland Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 122. Poland Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 123. Poland Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 124. Poland Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 125. South America Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 126. South America Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 127. South America Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 128. South America Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 129. South America Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 130. South America Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 131. South America Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 132. South America Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 133. South America Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F

Figure 134. Brazil Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 135. Brazil Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 136. Brazil Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 137. Brazil Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 138. Brazil Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 139. Brazil Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 140. Brazil Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 141. Brazil Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 142. Argentina Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 143. Argentina Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 144. Argentina Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 145. Argentina Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 146. Argentina Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 147. Argentina Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 148. Argentina Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 149. Argentina Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 150. Asia-Pacific Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 151. Asia-Pacific Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 152. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 153. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 154. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 155. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 156. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 157. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 158. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F

Figure 159. India Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 160. India Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 161. India Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 162. India Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 163. India Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 164. India Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 165. India Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 166. India Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 167. China Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 168. China Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 169. China Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 170. China Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 171. China Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 172. China Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 173. China Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 174. China Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 175. Japan Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 176. Japan Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 177. Japan Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 178. Japan Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 179. Japan Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 180. Japan Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 181. Japan Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 182. Japan Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 183. Australia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 184. Australia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 185. Australia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 186. Australia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 187. Australia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 188. Australia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 189. Australia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 190. Australia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 191. Vietnam Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 192. Vietnam Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 193. Vietnam Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 194. Vietnam Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 195. Vietnam Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 196. Vietnam Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 197. Vietnam Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 198. Vietnam Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 199. South Korea Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 200. South Korea Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 201. South Korea Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 202. South Korea Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 203. South Korea Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 204. South Korea Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 205. South Korea Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 206. South Korea Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 207. Indonesia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 208. Indonesia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 209. Indonesia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 210. Indonesia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 211. Indonesia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 212. Indonesia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 213. Indonesia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 214. Indonesia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 215. Philippines Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 216. Philippines Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 217. Philippines Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 218. Philippines Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 219. Philippines Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 220. Philippines Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 221. Philippines Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 222. Philippines Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 223. Middle East & Africa Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 224. Middle East & Africa Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 225. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 226. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 227. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 228. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 229. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 230. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 231. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F

Figure 232. Saudi Arabia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 233. Saudi Arabia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 234. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 235. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 236. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 237. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 238. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 239. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 240. UAE Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 241. UAE Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 242. UAE Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 243. UAE Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 244. UAE Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 245. UAE Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 246. UAE Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 247. UAE Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 248. South Africa Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F

Figure 249. South Africa Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F

Figure 250. South Africa Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F

Figure 251. South Africa Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F

Figure 252. South Africa Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F

Figure 253. South Africa Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F

Figure 254. South Africa Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F

Figure 255. South Africa Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F

Figure 256. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 257. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 258. By Setting Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 259. By Type of Testing Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 260. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 261. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023 

List of Tables

Table 1. Pricing Analysis of Products from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

What are the regions covered in the final report for global infectious disease diagnostics market?

arrowup
Heart

Global E-bike Battery Market Assessment, Opportunities and Forecast, 2017-2031F

The increased popularity of e-bikes along with the increasing adoption of compact vehicles for adventure sport and exploration is propelling the market expansion. ....Read More

Published on

April 2024

4,500

Heart

Global Chloroxylenol Market Assessment, Opportunities and Forecast, 2017-2031F

Global chloroxylenol market is expected to experience significant growth over the forecast period owing to the antimicrobial properties of chloroxylenol, increasing emphasis on maintaining skin health and personal hygiene, and growing threat of surgi....Read More

Published on

April 2024

4,500

Heart

Global Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F

Global gabapentin market will experience significant growth over the forecast period due to the rising investments in product innovation activities by the pharmaceutical companies and increasing incidences of seizures.....Read More

Published on

April 2024

4,500

Heart

Global Magnesium Citrate Market Assessment, Opportunities and Forecast, 2017-2031F

Global magnesium citrate market will witness significant growth over the forecast period owing to rapid expansion of the pharmaceutical sector and increasing research and development activities.....Read More

Published on

April 2024

4,500

Purchase Options

USD ($)

arrowdown

i

3,000

i

4,500

i

5,700

i

8,200

Tired of Searching?

Looking for Customization?

Some other doubt?

Need insights from a cohort?

REACH US

    icon_Five
    17, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi 110020
    call_Two
    +91 11 42343567
    icon_Six
    info@marketsandata.com
icon_Seven
5741 Cleveland street, Suite 120, VA beach, VA, USA 23462
call_Three
+1 (757) 343-3258
icon_Eight
190 Middle Road, # 14-10 Fortune Centre, Singapore -188979